Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Shares Bought by Magnus Financial Group LLC

Magnus Financial Group LLC raised its stake in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) by 12.9% in the third quarter, HoldingsChannel reports. The fund owned 35,000 shares of the company’s stock after purchasing an additional 4,000 shares during the period. Magnus Financial Group LLC’s holdings in Checkpoint Therapeutics were worth $78,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. XTX Topco Ltd purchased a new stake in shares of Checkpoint Therapeutics in the second quarter valued at approximately $34,000. 180 Wealth Advisors LLC purchased a new stake in shares of Checkpoint Therapeutics in the second quarter valued at approximately $96,000. Choreo LLC increased its position in shares of Checkpoint Therapeutics by 200.9% in the first quarter. Choreo LLC now owns 57,922 shares of the company’s stock valued at $119,000 after buying an additional 38,672 shares in the last quarter. PVG Asset Management Corp purchased a new stake in shares of Checkpoint Therapeutics in the second quarter valued at approximately $295,000. Finally, B. Riley Wealth Advisors Inc. increased its position in shares of Checkpoint Therapeutics by 232.3% in the fourth quarter. B. Riley Wealth Advisors Inc. now owns 163,350 shares of the company’s stock valued at $374,000 after buying an additional 114,200 shares in the last quarter. 22.00% of the stock is owned by institutional investors and hedge funds.

Checkpoint Therapeutics Stock Performance

Shares of CKPT opened at $2.82 on Thursday. Checkpoint Therapeutics, Inc. has a one year low of $1.36 and a one year high of $3.62. The stock has a market capitalization of $100.63 million, a price-to-earnings ratio of -1.02 and a beta of 1.30. The stock has a 50 day moving average price of $2.30 and a 200 day moving average price of $2.08.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.11. The firm had revenue of $0.04 million for the quarter. On average, analysts predict that Checkpoint Therapeutics, Inc. will post -0.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Checkpoint Therapeutics in a research report on Monday, September 16th.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.